UK markets closed

Lysogene S.A. (0RNL.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
2.0342-0.1228 (-5.69%)
At close: 4:59PM BST
Full screen
Previous close2.1570
Open2.0342
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range2.0342 - 2.0342
52-week range2.0342 - 2.0342
Volume1,777
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)0.48
PE ratio (TTM)N/A
EPS (TTM)-0.5880
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Lysogene Announces a Presentation of its LYS-GM101 Program at the ESGCT 2021

    PARIS, October 18, 2021--Regulatory News: Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces today that it will give an oral presentation at the ESGCT 2021 Annual Virtual Conference on its gene therapy drug candidate LYS-GM101 in GM1 gangliosidosis.

  • Business Wire

    Lysogene Reports its Cash Position as of 30 September 2021

    PARIS, October 08, 2021--Regulatory News: Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today reports its cash position of €9.5 million1 as of 30 September 2021 (compared to €15.0 million as of 30 June 2021).

  • Business Wire

    LYSOGENE Reports First Half 2021 Financial Results and Provides Operational Update

    PARIS, September 24, 2021--Regulatory News: Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announced its financial results for the first half 2021, approved by the Board of Directors on 23 September 2021. The financial statements were subject to a limited review by the Company’s statutory auditors. The full interim financial report is available on the Company’s website in the Investors’ section.